Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
4h agoAmerican Pacific Reports Underground Assays from Breccia Pipe and Decline Sampling at Madison Project
4h agoLake Victoria Gold Reports Geotechnical Results Supporting Final Pit Design and Advancing Development at Imwelo
4h agoAustin Gold Announces Results of 2026 Annual General Meeting
4h agoCactus Announces First Quarter 2026 Results
4h agoViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Chimeric Therapeutics Limited Temp logo

Chimeric Therapeutics Limited Temp

About

Chimeric Therapeutics Limited Temp — investor relations, events, news, and company updates on 6ix.

Latest News

Apr 29 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Apr 27 2026
CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi

Community Chat

Ask AI

6ix6ixAIEvents